Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) released its earnings results on Tuesday. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.09, Zacks reports. The business had revenue of $907.84 million during the quarter, compared to the consensus estimate of $890.88 million.

Swedish Orphan Biovitrum Price Performance

Shares of OTCMKTS BIOVF opened at $45.72 on Wednesday. The stock’s 50-day moving average is $46.21 and its 200 day moving average is $44.07. Swedish Orphan Biovitrum has a 1-year low of $34.88 and a 1-year high of $49.03.

Wall Street Analyst Weigh In

BIOVF has been the topic of a number of research analyst reports. Pareto Securities upgraded Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Finally, Nordea Equity Research cut shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, October 22nd. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Swedish Orphan Biovitrum has a consensus rating of “Moderate Buy”.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.